Evidence map›Paper›PMID 27752872›Full record

ArticleAIDS and behavior2017

Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort.

Catherine R Lesko, Weiqun Tong, Richard D Moore, Bryan Lau

Open access · greenAbstract read
In one paragraph

Article in AIDS and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Catherine R LeskoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD, 21205, USA. clesko2@jhu.edu.
Weiqun TongDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD, 21205, USA.
Richard D MooreDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD, 21205, USA.
Bryan LauDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD, 21205, USA.
Johns Hopkins University · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)U01AA020793 · NIAAA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., LAU, BRYAN · 2011 to 2020
$5.8M
NIAAA NIH HHS U01 AA020793NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069918NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

Compared to HIV-infected persons who do not inject drugs (non-IDU), persons who inject drugs (PWID) experience disparities in linking to medical care, initiating antiretroviral therapy (ART) and achieving viral suppression. There has been little attention to changes in these disparities over time. We estimated the proportion of PWID and non-IDU retained in care, on ART, and virally suppressed each year from 2001-2012 in the Johns Hopkins HIV Clinical Cohort (JHHCC). We defined active clinic patients as those who had ≥1 clinical visit, CD4 cell count, or viral load between July 1 of the prior year, and June 30 of the analysis year. Within a calendar year, retention was defined as ≥2 clinical visits or HIV-related laboratory measurements >90 days; ART use was defined as ≥1 ART prescription active ≥30 days; and viral suppression was defined as ≥1 HIV viral load <400 copies/mL. While PWID were less likely to be retained in earlier years, the gaps in retention closed around 2010. After 2003-2004, PWID and non-IDU retained in care had similar probability of receiving a prescription for ART and PWID and non-IDU on ART had similar probability of viral suppression.

Indexed as

Patient ComplianceAdolescentAdultAnti-HIV AgentsBaltimoreCD4 Lymphocyte CountCohort StudiesFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedOutpatient Clinics, HospitalSubstance Abuse, IntravenousUrban PopulationAnti-HIV AgentsAntiretroviral therapyHIV care continuumInjection drug useViral load suppression

Identifiers

PMID27752872
PMCPMC5344751
OpenAlexW2535083635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.